AVIR (Atea Pharmaceuticals) Buyback Yield %: 7.16 (As of Jun. 30, 2026) — 185% Above Median


AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.61
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Buyback Yield %?

Atea Pharmaceuticals AVIR +2.67% 24 Buyback Yield % is 7.16 as of Jun. 30, 2026, which is 185% above its 10-year median of 2.51. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 742 Biotechnology companies, Atea Pharmaceuticals ranks better than 98.92% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Atea Pharmaceuticals's current buyback yield was 7.16%.

Atea Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Atea Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atea Pharmaceuticals Buyback Yield % Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -0.20 -0.06 0.00 0.00 9.13

Atea Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 4.82 11.26 9.13 5.97

AVIR vs VNDA, TENX, OABI: Buyback Yield % Comparison

For the Biotechnology subindustry, Atea Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Buyback Yield % falls into.


AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atea Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Atea Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-25.519 + 0.058) / 278.91339
=9.13%

Atea Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-25.722 + 0) / 430.54526
=5.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 7.16 mean?
Atea Pharmaceuticals (AVIR) has a Buyback Yield % of 7.16 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Atea Pharmaceuticals and its competitors. This is 185% above median its historical median of 2.51. According to the industry distribution chart, Atea Pharmaceuticals ranks #8 out of 742 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Atea Pharmaceuticals' Buyback Yield % too high?
Atea Pharmaceuticals' current Buyback Yield % of 7.16 is 185% above median its 10-year median of 2.51. Based on the distribution chart, Atea Pharmaceuticals ranks #8 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Buyback Yield % compare to VNDA and TENX?
According to the Biotechnology industry distribution chart, Atea Pharmaceuticals ranks #8 out of 742 companies for Buyback Yield %. This places Atea Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Atea Pharmaceuticals and its competitors. Atea Pharmaceuticals's current Buyback Yield % is 7.16, which is 185% above median its own 10-year median of 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Buyback Yield % of 7.16. The current Buyback Yield % is 7.16, which is 185% above median its 10-year median of 2.51. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Buyback Yield % is 7.16 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price